ArticleLeukemia2014
Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.
Abstract readCase ReportsLetter
In one paragraph
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed.
- Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients.Leukemia · 2020Trial
- Article
- STAT5B leukemic mutations, altering SH2 tyrosine 665, have opposing impacts on immune gene programs.Life science alliance · 2025Article
- Infections in Inborn Errors of STATs.Pathogens (Basel, Switzerland) · 2024Review
- PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.NPJ precision oncology · 2024Article
- Article
- Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.The Journal of clinical investigation · 2024Article
- Targeting of STAT5 using the small molecule topotecan hydrochloride suppresses acute myeloid leukemia progression.Oncology reports · 2023Article
- STAT5b gain-of-function disease in a child with mycobacterial osteomyelitis of the skull: rare presentation of an emerging disease entity.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023Review
- Review
- STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation ofHaematologica · 2023Article
- Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia.Blood advances · 2023Article
- Article
- Comparative Efficacy of AZD9496 and Fulvestrant on the Growth of Pituitary Adenoma via Blocking JAK2/STAT5B Pathway.Journal of Cancer · 2023Article
- Uncovering novel mutational signatures byCell genomics · 2022Article
- Genomic Mutations of the STAT5 Transcription Factor Are Associated with Human Cancer and Immune Diseases.International journal of molecular sciences · 2022Review
- Identification of novel STAT5B mutations and characterization of TCRβ signatures in CD4+ T-cell large granular lymphocyte leukemia.Blood cancer journal · 2022Article
- Article
- Reactive Oxygen Species in Acute Lymphoblastic Leukaemia: Reducing Radicals to Refine Responses.Antioxidants (Basel, Switzerland) · 2021Review
- Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma.Blood · 2021Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
M KontroHematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland.
H Kuusanmäki1] Hematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland [2] Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
S EldforsInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
T BurmeisterDepartment of Hematology, Oncology, and Tumor Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany.
E I AnderssonHematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland.
O Bruserud1] Department of Clinical Science, Hematology Section, University of Bergen, Bergen, Norway [2] Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.
T H BrümmendorfDepartment of Oncology, Hematology and Stem Cell Transplantation, University Hospital Aachen, RWTH Aachen University, Aachen, Germany.
H EdgrenInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
B T Gjertsen1] Department of Clinical Science, Hematology Section, University of Bergen, Bergen, Norway [2] Department of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway.
M Itälä-RemesDepartment of Clinical Hematology, Turku University Central Hospital, University of Turku, Turku, Finland.
S LagströmInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
O LohiTampere Center for Child Health Research, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland.
T LundánDepartment of Clinical Chemistry and TYKSLAB, Turku University Central Hospital, University of Turku, Turku, Finland.
J M L MartíInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
M M MajumderInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
A ParsonsInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
T PemovskaInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
H RajalaHematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland.
K VettenrantaDivision of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland.
O KallioniemiInstitute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
S MustjokiHematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland.
K PorkkaHematology Research Unit Helsinki, Department of Medicine, University of Helsinki and Helsinki University Central Hospital Cancer Center, Helsinki, Finland.
C A Heckman1] Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland [2] Institute of Biomedicine, University of Helsinki, Helsinki, Finland.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAdolescentbcl-X ProteinHumansPrecursor T-Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-bcl-2STAT5 Transcription FactorBCL2L1 protein, humanbcl-X ProteinProto-Oncogene Proteins c-bcl-2STAT5B protein, humanSTAT5 Transcription Factor
Identifiers
PMID
24573384What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.